CoChat

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy. Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.

Overview

Integrity signals

Registry

Crossref · 10.1097/crd.0000000000000513

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 61

Metadata

Authors
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H.
Affiliations
  • New York Medical College (US)
  • Westchester Medical Center (US)
Corresponding author
D’Ascanio, Antonella M.
Venue
Cardiology in Review
Published
2023-10-20
Volume
32
Issue
1
Pages
83-90
ISSN
1061-5377 (ISSN-L)
OpenAlex
W4323533074
Cited by
46
References
22
Citations by year
2026: 17 · 2025: 20 · 2024: 6 · 2023: 3
FWCI
7.14
Type
journal article
Language
en
Open access
closed
Locations
  • Cardiology in Review (publishedVersion)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
cagrilintide, amylin analogues, obesity treatment, semaglutide, GLP-1 receptor agonists, combination therapy, weight loss, appetite suppression, satiety, glucagon, glucagon-like peptide-1, pancreatic beta cells, pharmacotherapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Obesity, Weight Loss, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. https://app.cochat.ai/papers/10.1097/crd.0000000000000513
The paper
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review. https://doi.org/10.1097/crd.0000000000000513

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.